A trial evaluated the short-term oncologic efficacy of cooled focal therapy ablation using the ProFocal device in men with localized, intermediate-risk prostate cancer.

Machine design engineers working in the medical device field might draw inspiration from AuraWell’s iterative, ...

A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...

The National Healthtech Access Programme aims to improve accessibility to healthtech products across the NHS.

A novel, cooled laser focal therapy (cLFT) exhibits high treatment success for localized prostate cancer (PCa), according to a study published online Jan. 28 in ...

Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Fourth Quarter and Full Year 2025 Results Conference ...

Median Technologies’ eyonis (LCS) software, which recently gained FDA clearance, will be integrated into Tempus AI’s cardiac imaging platform.

Scientists are using spider silk to help develop surgical devices for nerve regeneration. "It acts like a scaffold for nerves ...

Detailed price information for Profound Medical Corp (PROF-Q) from The Globe and Mail including charting and trades.

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage innovator in interventional MRI (“iMRI”) procedures, is pleased to announce that it has received the ...

Siemens Healthineers announced that it agreed to expand its strategic collaboration with Mayo Clinic to enhance patient care.

Prostate cancer is the second most frequent cancer diagnosis made in men, and the fifth leading cause of death worldwide. To break that down, one in five men will get prostate cancer globally. To ...